Cellectis Moves First Off-The-Shelf CAR-T Into US Clinical Trials

UCART123 is behind the initial wave of CAR-T drugs for cancer but could have a big advantage as an allogeneic, or off-the-shelf, option. A Phase I trial is now under way in patients with acute myeloid leukemia.